Oncimmune Holdings (GB:ONC) has released an update.
Oncimmune Holdings PLC, renowned for its autoantibody profiling capabilities, has secured a lucrative $1.5 million contract with a Top 10 Global Pharma company, signaling one of its most substantial ImmunoINSIGHTS business deals to date and showcasing its prowess in repeat business. The deal, focusing on a technological breakthrough in immunoglobulin E (IgE) profiling, is expected to significantly contribute to the firm’s FY2025 revenue and drive the company towards profitability. Optimism from the board regarding financial targets for FY2024 and discussions with IPF Management SA about amending credit terms highlight Oncimmune’s strong strategic positioning and growth trajectory.
For further insights into GB:ONC stock, check out TipRanks’ Stock Analysis page.
